Clinical Trial Update: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for a pegylated recombinant Factor VIII-Fc fusion protein in severe Hemophilia A is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (pegylated recombinant coagulation factor VIII-Fc fusion protein)

Snippet

Sponsor: Jiangsu Gensciences lnc. | Conditions: Severe Hemophilia A | Phase 3 | Status: RECRUITING